MX2015016418A - Dihidroetorfina para proporcionar el alivio del dolor y la anestesia. - Google Patents
Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.Info
- Publication number
- MX2015016418A MX2015016418A MX2015016418A MX2015016418A MX2015016418A MX 2015016418 A MX2015016418 A MX 2015016418A MX 2015016418 A MX2015016418 A MX 2015016418A MX 2015016418 A MX2015016418 A MX 2015016418A MX 2015016418 A MX2015016418 A MX 2015016418A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydroetorphine
- pain relief
- anaesthesia
- provision
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Dermatology (AREA)
Abstract
La presente invención incluye un método para proporcionar el alivio del dolor en un paciente humano en necesidad del mismo, que comprende administrar (R)-dihidroetorfina a dicho paciente, donde dicha (R)-dihidroetorfina se administra en una dosis de al menos 0.01 mg/kg, preferiblemente de al menos 0.05 mg/kg, y el nivel de depresión respiratoria en dicho paciente es de 65% o menor con relación al nivel de referencia antes de la administración de (R)-dihidroetorfina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1309654.0A GB201309654D0 (en) | 2013-05-30 | 2013-05-30 | Method |
PCT/GB2014/000206 WO2014191710A1 (en) | 2013-05-30 | 2014-05-30 | Dihydroetorphine for the provision of pain relief and anaesthesia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015016418A true MX2015016418A (es) | 2016-11-08 |
Family
ID=48805475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015016418A MX2015016418A (es) | 2013-05-30 | 2014-05-30 | Dihidroetorfina para proporcionar el alivio del dolor y la anestesia. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10898479B2 (es) |
EP (1) | EP3003310A1 (es) |
JP (3) | JP2016520114A (es) |
KR (1) | KR20160013977A (es) |
CN (1) | CN105555274A (es) |
AU (1) | AU2014272924B2 (es) |
BR (1) | BR112015029709A2 (es) |
CA (1) | CA2913849A1 (es) |
GB (1) | GB201309654D0 (es) |
HK (1) | HK1222585A1 (es) |
MX (1) | MX2015016418A (es) |
PH (1) | PH12015502655A1 (es) |
WO (1) | WO2014191710A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102051800B1 (ko) | 2011-03-04 | 2019-12-04 | 그뤼넨탈 게엠베하 | 경구 투여를 위한 타펜타돌의 수성 약제학적 제형 |
EP3479823B1 (en) | 2015-03-27 | 2020-09-09 | Grünenthal GmbH | Stable formulation for parenteral administration of tapentadol |
GB201513442D0 (en) * | 2015-07-30 | 2015-09-16 | Euro Celtique Sa | Transdermal patch |
EP3515412A1 (en) | 2016-09-23 | 2019-07-31 | Grünenthal GmbH | Stable formulation for parenteral administration of tapentadol |
WO2018153947A1 (en) | 2017-02-23 | 2018-08-30 | Grünenthal GmbH | Tapentadol as local anesthetic |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB925723A (en) | 1960-09-05 | 1963-05-08 | J F Macfarlan & Company Ltd | Novel thebaine derivatives |
GB937214A (en) | 1961-06-02 | 1963-09-18 | J F Macfarlan & Company Ltd | Oripavine derivatives |
JPS59184182A (ja) | 1983-04-02 | 1984-10-19 | Res Inst For Prod Dev | 3−ベンゾイルチオ−4、5α−エポキシ−7α−〔1(R)−ヒドロキシ−1−メチルベンチル〕−6−メトキシ−17−メチル−6、14−エンド−エタノモルヒナン |
JPS62153214A (ja) | 1985-12-26 | 1987-07-08 | Nitto Electric Ind Co Ltd | 医薬製剤 |
JPS62281815A (ja) | 1986-05-27 | 1987-12-07 | Teisan Seiyaku Kk | 貼付剤及びその製造法 |
JPS63201119A (ja) | 1987-02-17 | 1988-08-19 | Kao Corp | 貼付剤組成物 |
US4891377A (en) | 1988-12-02 | 1990-01-02 | Board Of Regents Acting For And On Behalf Of University Of Michigan | Transdermal delivery of the narcotic analgesics etorphine and analogs |
PT95069B (pt) | 1989-08-24 | 1997-10-31 | Searle & Co | Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos |
US5271940A (en) | 1989-09-14 | 1993-12-21 | Cygnus Therapeutic Systems | Transdermal delivery device having delayed onset |
US5633259A (en) | 1992-09-21 | 1997-05-27 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
EP0668764A1 (en) | 1992-09-21 | 1995-08-30 | QIN, Bo-yi | Methods for identifying and using low/non-addictive opioid analgesics |
JP2819236B2 (ja) | 1994-05-06 | 1998-10-30 | 日東電工株式会社 | 経皮吸収製剤 |
DE69625483T3 (de) | 1995-06-07 | 2012-05-10 | Ortho-Mcneil Pharmaceutical, Inc. | Transdermales pflaster zur verabreichung von 17-deacetyl norgestimat in kombination mit einem östrogen |
AUPN603895A0 (en) | 1995-10-19 | 1995-11-09 | University Of Queensland, The | Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids |
US6103258A (en) | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
KR100204659B1 (ko) | 1996-05-28 | 1999-06-15 | 강재헌 | 신규한 부프레노핀계 진통제용 화합물 |
JPH10231248A (ja) | 1997-02-19 | 1998-09-02 | T T S Gijutsu Kenkyusho:Kk | ジヒドロエトルフィン含有経皮吸収型製剤 |
NZ504618A (en) | 1998-08-27 | 2002-09-27 | Pharmacia & Upjohn Ab | Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level |
US6194382B1 (en) | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
US6312716B1 (en) | 1999-05-10 | 2001-11-06 | Peierce Management Llc | Patch and method for transdermal delivery of bupropion base |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
JP4659943B2 (ja) | 2000-02-25 | 2011-03-30 | 帝三製薬株式会社 | 塩酸ブプレノルフィン含有貼付剤 |
MX342305B (es) | 2000-04-26 | 2016-09-23 | Watson Pharmaceuticals Inc * | Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina. |
US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
AU782523B2 (en) | 2000-07-13 | 2005-08-04 | Euro-Celtique S.A. | Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
JP2005500373A (ja) | 2001-08-10 | 2005-01-06 | ポリチップ ファーマスーティカルズ プロプライエタリイ リミテッド | モルヒネ様オピオイド化合物の誘導体 |
CN1233645C (zh) | 2001-09-14 | 2005-12-28 | 中国人民解放军军事医学科学院毒物药物研究所 | 新的东罂粟碱衍生物及其医药用途 |
US20040024005A1 (en) | 2002-01-23 | 2004-02-05 | The Regents Of The University Of California | Methods and compositions for reducing the development of drug tolerance and/or physical dependence |
US20060177381A1 (en) | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
US20040033253A1 (en) | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
WO2003101433A1 (de) | 2002-05-28 | 2003-12-11 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Pflaster, enthaltend fentanylum |
WO2003103673A1 (en) | 2002-06-10 | 2003-12-18 | Purdue Pharma, L.P. | Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
ATE423560T1 (de) | 2002-08-20 | 2009-03-15 | Euro Celtique Sa | Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form |
AU2002951965A0 (en) | 2002-10-09 | 2002-10-24 | Monash University | Amidine compounds |
TWI296531B (en) | 2002-10-18 | 2008-05-11 | Hisamitsu Pharmaceutical Co | Transdermal adhesive preparations for topical administration of fentanyl |
TW200500067A (en) | 2003-01-21 | 2005-01-01 | Control Delivery Sys Inc | Salts of codrugs and uses related thereto |
US20040208917A1 (en) | 2003-04-16 | 2004-10-21 | Wilfried Fischer | Transdermal systems for the release of clonidine |
CL2004000927A1 (es) | 2003-04-30 | 2005-01-28 | Purdue Pharma Lp | Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal. |
US20050113365A1 (en) | 2003-11-10 | 2005-05-26 | Sir Isaac Newton Enterprises Llc | Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome |
CN100500151C (zh) | 2004-04-02 | 2009-06-17 | 北京万全阳光医药科技有限公司 | 一种水溶性药物舌下给药制剂 |
JP2007538091A (ja) | 2004-05-17 | 2007-12-27 | ファーマコフォア・インコーポレイテッド | 痛みを処置または予防するための組成物および方法 |
AU2006235318A1 (en) | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
WO2007004067A2 (en) | 2005-04-15 | 2007-01-11 | Interface Biologics Inc. | Methods and compositions for the delivery of biologically active agents |
KR100764679B1 (ko) | 2005-07-22 | 2007-10-09 | 익수제약 주식회사 | 파록세틴을 함유하는 경피투여용 패취제 |
US8163701B2 (en) | 2005-08-19 | 2012-04-24 | Signature Therapeutics, Inc. | Prodrugs of active agents |
WO2007052308A2 (en) | 2005-11-03 | 2007-05-10 | Brain N' Beyond Biotech Pvt. Ltd. | Glyco-phosphorylated biologically active agents |
GB0523031D0 (en) | 2005-11-11 | 2005-12-21 | Yaupon Therapeutics | Enhancement of morphine analgesia by s(-)-norketamine |
TWI389709B (zh) | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
US8071125B2 (en) | 2005-12-09 | 2011-12-06 | Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. | Transdermal patch containing isosorbide dinitrate and bisoprolol |
JP2009530307A (ja) | 2006-03-15 | 2009-08-27 | アルザ コーポレイション | 骨減少症を予防し、または治療するための副甲状腺ホルモン薬の経皮送達のための装置、並びに方法 |
USD576282S1 (en) | 2006-06-16 | 2008-09-02 | Activatek, Inc. | Adhesive transdermal medicament patch |
USD625017S1 (en) | 2006-08-11 | 2010-10-05 | Hisamitsu Pharmaceutical Co., Inc. | Medical transdermal patch |
DE102006050558B4 (de) | 2006-10-26 | 2009-03-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution |
CN100512817C (zh) | 2006-11-15 | 2009-07-15 | 闫章年 | 复方噻拉嗪注射液及制备工艺 |
DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
JP2010514789A (ja) | 2006-12-27 | 2010-05-06 | アベール ファーマシューティカルズ インコーポレイテッド | 副腎皮質ステロイド投与のための経皮的方法及びパッチ |
WO2008109156A2 (en) | 2007-03-06 | 2008-09-12 | Mallinckrodt Inc. | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
CN101147739B (zh) | 2007-07-06 | 2010-12-08 | 北京康倍得医药技术开发有限公司 | 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂 |
KR100929560B1 (ko) | 2008-01-09 | 2009-12-03 | 에코 퍼시픽 엘티디 | 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제 |
EP2286814B1 (en) | 2008-05-15 | 2013-10-16 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal preparation containing palonosetron |
TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
EP2298277A1 (en) | 2009-09-09 | 2011-03-23 | Labtec GmbH | Transdermal patch formulation |
DE102010040299A1 (de) | 2010-09-06 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner) |
-
2013
- 2013-05-30 GB GBGB1309654.0A patent/GB201309654D0/en not_active Ceased
-
2014
- 2014-05-30 WO PCT/GB2014/000206 patent/WO2014191710A1/en active Application Filing
- 2014-05-30 CA CA2913849A patent/CA2913849A1/en not_active Abandoned
- 2014-05-30 AU AU2014272924A patent/AU2014272924B2/en not_active Ceased
- 2014-05-30 KR KR1020157036442A patent/KR20160013977A/ko not_active Application Discontinuation
- 2014-05-30 JP JP2016516232A patent/JP2016520114A/ja active Pending
- 2014-05-30 CN CN201480042250.XA patent/CN105555274A/zh active Pending
- 2014-05-30 US US14/894,775 patent/US10898479B2/en active Active
- 2014-05-30 EP EP14731983.4A patent/EP3003310A1/en not_active Ceased
- 2014-05-30 MX MX2015016418A patent/MX2015016418A/es unknown
- 2014-05-30 BR BR112015029709A patent/BR112015029709A2/pt not_active IP Right Cessation
-
2015
- 2015-11-27 PH PH12015502655A patent/PH12015502655A1/en unknown
-
2016
- 2016-09-15 HK HK16110921.5A patent/HK1222585A1/zh unknown
-
2019
- 2019-03-19 JP JP2019051613A patent/JP2019123730A/ja active Pending
-
2020
- 2020-09-17 JP JP2020156242A patent/JP2020200345A/ja active Pending
- 2020-09-30 US US17/038,651 patent/US20210085673A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2913849A1 (en) | 2014-12-04 |
CN105555274A (zh) | 2016-05-04 |
WO2014191710A1 (en) | 2014-12-04 |
JP2020200345A (ja) | 2020-12-17 |
US20160106736A1 (en) | 2016-04-21 |
US20210085673A1 (en) | 2021-03-25 |
EP3003310A1 (en) | 2016-04-13 |
KR20160013977A (ko) | 2016-02-05 |
AU2014272924A1 (en) | 2016-01-28 |
US10898479B2 (en) | 2021-01-26 |
JP2016520114A (ja) | 2016-07-11 |
JP2019123730A (ja) | 2019-07-25 |
BR112015029709A2 (pt) | 2017-07-25 |
HK1222585A1 (zh) | 2017-07-07 |
GB201309654D0 (en) | 2013-07-17 |
AU2014272924B2 (en) | 2019-05-02 |
PH12015502655A1 (en) | 2016-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN03219A (es) | ||
PH12016500619A1 (en) | Dry powder inhaler | |
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
MX2020002150A (es) | Terapia de combinación para el tratamiento del cáncer. | |
PH12014502058A1 (en) | Pharmaceutical composition comprising empagliflozin and antiobesity drug | |
PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
MX2021005317A (es) | Composiciones y métodos para absorción transmucosa. | |
EP4389213A3 (en) | Treatment of fabry disease in ert-naive and ert-experienced patients | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
UA98136C2 (ru) | Применение аклидиния для лечения респираторных заболеваний | |
PH12015502655A1 (en) | Method | |
MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
MX2016010892A (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica. | |
MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias |